Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:40
  • preuzimanja u poslednjih 30 dana:33

Sadržaj

članak: 1 od 13  
Back povratak na rezultate
2022, vol. 47, br. 2-3, str. 96-103
Inhibitori protonske pumpe - procena nuspojava i primena u COVID-19 infekciji
aInternistička ordinacija "Dr Bastać", Zaječar
bSpecijalistička ordinacija za internu medicinu "Dr Pavlović Kardiologija", Beograd

e-adresajoksaz@ptt.rs
Sažetak
Inhibitori protonske pumpe (IPP) su medu najčešće propisivanim lekovima. Njihova upotreba je verovatno čak i veća od procenjene zbog povećanja broja IPP dostupnih bez recepta. Ovi medikamenti se esto propisuju za neodgovarajuće indikacije ili nepotrebno dug tretman. Povećana upotreba IPP u poslednje dve decenije dovela je u pitanje dugorotne efekte ovih lekova. Postoje podaci opservacionih studija koji upućuju da IPP u dugotrajnoj upotrebi povećavaju rizik za hronične bolesti bubrega, demenciju, osteoporozu, pneumoniju, infekcije gastrointestinalnog trakta, malapsorpciju minerala i vitamina B12, kao i da povećavaju rizik od infekcije i težeg toka bolesti COVID-19. Ipak, navedene sumnje još nemaju dovoljno dokaza da potvrde uzročnu vezu poremećaja i korišćenja IPP, a i kada postoji primećen rizik on je uglavnom Mali. Postoji potreba za kvalitetnijim studijama koje istražuju ovaj odnos. Inhibitor protonske pumpe propisani za odgovarajuću indikaciju i za odgovarajuće trajanje letenja su i dalje bezbedni lekovi koji pacijentima donose više koristi nego rizika.
Reference
Abrahami, D., McDonald, E.G., Schnitzer, M.E., Barkun, A.N., Suissa, S., Azoulay, L. (2022) Proton pump inhibitors and risk of gastric cancer: Population-based cohort study. Gut, 71(1): 16-24
Agewall, S., Cattaneo, M., Collet, J.P., Andreotti, F., Lip, G.Y.H., Verheugt, F.W.A., Huber, K., Grove, E.L., Morais, J., Husted, S., Wassmann, S., Rosano, G., Atar, D., Pathak, A., Kjeldsen, K., Storey, R.F. (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European Heart Journal, 34(23): 1708-1713
Ahn, J.S., Eom, C.S., Jeon, C.Y., Min, P.S. (2013) Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World Journal of Gastroenterology, 19(16):2560-8
Almario, C.V., Chey, W.D., Spiegel, B. (2020) Increased risk of COVID-19 among users of Proton Pump Inhibitors. Am J Gastroenterol, 115(10): 1707-1715
Antoniou, T., Macdonald, E.M., Hollands, S., Gomes, T., Mamdani, M.M., Garg, A.X., Paterson, J.M., Juurlink, D.N. (2015) Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open, 3(2): E166-E171
Arora, P., Gupta, A., Golzy, M., Patel, N., Carter, R.L., Jalal, K., Lohr, J.W. (2016) Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrology, 17(1): 116-116
Attwood, S.E., Ell, C., Galmiche, J.P., Fiocca, R., Hatlebakk, J.G., Hasselgren, B., Långström, G., Jahreskog, M., Eklund, S., Lind, T., Lundell, L. (2015) Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: Data from the SOPRAN and LOTUS studies. Alimentary Pharmacology & Therapeutics, 41(11): 1162-1174
Bavishi, C., Dupont, H.L. (2011) Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacology & Therapeutics, 34(11-12), 1269-1281
Bjorkman, D.J., Estborn, L., Joelson, S. (2015) Esomeprazole and respiratory tract infections. Aliment Pharmacol Ther, https://www.jwatch.org/na38529/2015/07/24/eso meprazole-and-respiratory-tract-infections (preuzeto 01.08.2022)
Blank, M.L., Parkin, L., Paul, C., Herbison, P. (2014) A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney International, 86(4): 837-844
Brophy, S., Jones, K.H., Rahman, M.A., Zhou, S.M., John, A., Atkinson, M.D., Francis, N., Lyons, R.A., Dunstan, F. (2013) Incidence of campylobacter and salmonella infections following first prescription for PPI: A cohort study using routine data. American Journal of Gastroenterology, 108(7): 1094-1100
Brunner, G., Athmann, C., Schneider, A. (2012) Long-term, open-label trial: Safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Alimentary Pharmacology & Therapeutics, 36(1): 37-47
Cardoso, R.N., Benjo, A.M., Dinicolantonio, J.J., Garcia, D.C., Macedo, F.Y.B., El-Hayek, G., Nadkarni, G.N., Gili, S., Iannaccone, M., Konstantinidis, I., Reilly, J.P. (2015) Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: An updated meta-analysis. Open Heart, 2(1): e000248-e000248
Cheng, Z., Liu, Y., Ma, M., Sun, S., Ma, Z., Wang, Y., Yu, L., Qian, X., Sun, L., Zhang, X., Liu, Y., Wang, Y. (2022) Lansoprazole-induced osteoporosis via the IP3Rand SOCE-mediated calcium signaling pathways. Molecular Medicine, 28(1): 21-21
Clooney, A.G., Bernstein, C.N., Leslie, W.D., Vagianos, K., Sargent, M., Laserna-Mendieta, E.J., Claesson, M.J., Targownik, L.E. (2016) A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(9): 974-984
Cooksey, R., Kennedy, J., Dennis, M.S., Escott-Price, V., Lyons, R.A., Seaborne, M., Brophy, S. (2020) Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One, 15(9): e0237676-e0237676
Estborn, L., Joelson, S. (2015) Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: A retrospective analysis of patient-level data in placebo-controlled studies. Alimentary Pharmacology & Therapeutics, 42(5): 607-613
Fatima, K., Almas, T., Lakhani, S., Jahangir, A., Siddiqui, A.A., et al. (2022) The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop Med Infect Dis, 7(3): 37-37; PMCID: PMC8950138
Filion, K.B., Chateau, D., Targownik, L.E., Gershon, A., Durand, M.A., Tamim, H., Teare, G.F., Ravani, P.F., Ernst, P., Dormuth, C.R. (2014) Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: Replicated cohort studies with meta-analysis. Gut, 63(4): 552-558
Funck-Brentano, C., Szymezak, J., Steichen, O., Ducint, D., Molimard, M., et al. (2013) Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis, 106(12):661-71; Epub 2013 Nov 15
Goldstein, F.C., Steenland, K., Zhao, L., Wharton, W., Levey, A.I., Hajjar, I. (2017) Proton pump inhibitors and risk of mild cognitive impairment and dementia. J Am Geriatr Soc, 65(9): 1969-74
Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Fink, A., et al. (2016) Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol, 73(4): 410-416
Gray, S.L., Lacroix, A.Z., Larson, J., Robbins, J., Cauley, J.A., Manson, J.E., et al. (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Archives of Internal Medicine, 170(9): 765-765
Haenisch, B., von Holt, K., Wiese, B., Prokein, J., Lange, C., Ernst, A., Brettschneider, C., König, H., Werle, J., Weyerer, S., Luppa, M., Riedel-Heller, S.G., Fuchs, A., Pentzek, M., Weeg, D. (2015) Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 265(5): 419-428
Hanžel, J., Golob, S., Štabuc, B. (2020) Neželeni učinki zaviralcev protonske črpalke in tveganje za potek bolezni COVID-19. Gastroenterolog, 2: 25-33
Janarthanan, S., Ditah, I., Adler, D.G., Ehrinpreis, M.N. (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol, 107(7): 1001-1010
Klatte, D.C.F., Gasparini, A., Xu, H., de Deco, P., Trevisan, M., Johansson, A.L.V., Wettermark, B., Ärnlöv, J., Janmaat, C.J., Lindholm, B., Dekker, F.W., Coresh, J., Grams, M.E., Carrero, J.J. (2017) Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology, 153(3): 702-710
Kow, C.S., Hasan, S.S. (2021) Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: A meta-analysis. Journal of Internal Medicine, 289(1): 125-128
Kwok, C.S., Arthur, A.K., Anibueze, C.I., Singh, S., Cavallazzi, R., Loke, Y.K. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol, 107(7): 1011-9
Lam, J.R., Schneider, J.L., Zhao, W., Corley, D.A. (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22):2435-42
Lam, J.R., Schneider, J.L., Quesenberry, C.P., Corley, D.A. (2017) Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology, 152(4):821-9.e1
Lambert, A.A., Lam, J.O., Paik, J.J., Ugarte-Gil, C., Drummond, M., Crowell, T.A. (2015) Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis. PLoS One, 10(6):e0128004
Lazarus, B., Chen, Y., Wilson, F.P., Sang, Y., Chang, A.R., Coresh, J., Grams, M.E. (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Internal Medicine, 176(2):238-46
Lee, S.W., Ha, E.K., Yeniova, A.Ö., Moon, S.Y., Kim, S.Y., Koh, H.Y., Yang, J.M., Jeong, S.J., Moon, S.J., Cho, J.Y., Yoo, I.K., Yon, D.K. (2021) Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut, 70(1): 76-84
Leonard, J., Marshall, J.K., Moayyedi, P. (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology, 102(9): 2047-2056
Li, J., Cao, J., Cai, P., Shi, B., Cao, J., Zhang, Y., Wang, J. (2020) Risk factors of secondary infections in severe and critical patients hospitalized with COVID-19: A case-control study. Research Square, Preprint
Lin, W.L., Muo, C.S., Lin, W.L., Hsieh, Y.W., Kao, C.H. (2019) Association of increased risk of pneumonia and using proton pump inhibitors in patients with type II diabetes mellitus. Dose-Response, 17(2):1559325819843383
Lochhead, P., Hagan, K., Joshi, A.D., Khalili, H., Nguyen, L.H., Grodstein, F., et al. (2017) Association between proton pump inhibitor use and cognitive function in women. Gastroenterology, 153(4):971-9.e4
Luxenburger, H., Sturm, L., Biever, P., Rieg, S., Duerschmied, D., Schultheiss, M., Neumann-Haefelin, C., Thimme, R., Bettinger, D. (2021) Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: Coincidence or underestimated risk factor?. Journal of Internal Medicine, 289(1): 121-124
Mckeigue, P.M., Kennedy, S., Weir, A., et al. (2021) Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study. BMC Med, 19(1): 51-51
Moledina, D.G., Perazella, M.A. (2016) PPIs and kidney disease: From AIN to CKD. Journal of Nephrology, 29(5): 611-616
Ngamruengphong, S., Leontiadis, G.I., Radhi, S., Dentino, A., Nugent, K. (2011) Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. American Journal of Gastroenterology, 106(7): 1209-1218
Ramachandran, P., Perisetti, A., Gajendran, M., Jean-Louis, F., Dwivedi, A.K., Goyal, H. (2020) Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19. medRxiv, Preprint; 2020.07.12.20151084
Rašić, J., Rašić, D., Janićijević-Hudomal, S., Nestorović, V. (2013) Inhibitori protonske pumpe - primena i bezbednost. Biomedicinska istraživanja, 4: 48-56; Pregled literature UDK: 616.333-008.8:615.03
Ray, A., Sharma, S., Sadasivam, B. (2020) The potential therapeutic role of proton pump inhibitors in COVID-19: Hypotheses based on existing evidences. Drug Res (Stuttg), 70(10):484-488; Epub 2020 Sep 2; PMCID: PMC7672704
Rosenberg, V., Tzadok, R., Chodick, G., Kariv, R. (2021) Proton pump inhibitors long term use-trends and patterns 15 y f organization. Pharmacoepidemiol Drug Saf, 30(11): 1576-1587
Sarzynski, E., Puttarajappa, C., Xie, Y., Grover, M., Laird-Fick, H. (2011) Association between proton pump inhibitor use and anemia: A retrospective cohort study. Digestive Diseases and Sciences, 56(8): 2349-2353
Savarino, V., Dulbecco, P., de Bortoli, N., Ottonello, A., Savarino, E. (2017) The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine, 37: 19-24
Schneider, J.L., Kolitsopoulos, F., Corley, D.A. (2016) Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(1): 73-82
Sharara, A.I., Chalhoub, J.M., Hammoud, N., Harb, A.H., Sarkis, F.S., Hamadeh, G. (2016) Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clinical Gastroenterology and Hepatology, 14(2): 317-321
Tai, S., Chien, C., Wu, D., Lin, K., Ho, B., Chang, Y., Chang, Y. (2017) Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One, 12(2): e0171006-e0171006
Taipale, H., Tolppanen, A., Tiihonen, M., Tanskanen, A., Tiihonen, J., Hartikainen, S. (2017) No association between proton pump inhibitor use and risk of Alzheimer's disease. American Journal of Gastroenterology, 112(12): 1802-1808
Targownik, L.E., Lix, L.M., Leung, S., Leslie, W.D. (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology, 138(3): 896-904
Taştemur, Ş., Ataseven, H. (2020) Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?. Med Hypotheses, 143:110018; Epub 2020 Jun 20
Tran-Duy, A., Spaetgens, B., Hoes, A.W., de Wit, N.J., Stehouwer, C.D.A. (2016) Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 14(12):1706-19
Vaezi, M.F., Yang, Y., Howden, C.W. (2017) Complications of proton pump inhibitor therapy. Gastroenterology, 153(1): 35-48
Xie, Y., Bowe, B., Li, T., Xian, H., Balasubramanian, S., Al-Aly, Z. (2016) Proton pump inhibitors and risk of incident CKD and progression to ESRD. Journal of the American Society of Nephrology, 27(10): 3153-3163
Zhou, B., Huang, Y., Li, H., Sun, W., Liu, J. (2016) Proton-pump inhibitors and risk of fractures: An update meta-analysis. Osteoporosis International, 27(1): 339-347
 

O članku

jezik rada: srpski, engleski
vrsta rada: pregledni članak
DOI: 10.5937/tmg2202096J
primljen: 18.06.2022.
objavljen onlajn: 04.11.2022.
objavljen u SCIndeksu: 26.11.2022.
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka